Search Results - "Bressler, Neil"

Artificial Intelligence With Deep Learning Technology Looks Into Diabetic Retinopathy Screening by Wong, Tien Yin, Bressler, Neil M

“…Gulshan and colleagues report the use of deep learning technology for diabetic retinopathy screening. Using large data sets of images to first "train" an…”
Get full text

Additional Information About Pegcetacoplan for Treatment of Geographic Atrophy Growth by Bressler, Neil M

Get more information

Safely Viewing a Solar Eclipse by Bressler, Neil M

Get more information

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T by Cai, Sophie, Bressler, Neil M

“…PURPOSE OF REVIEWThe aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial…”
Get full text

JAMA Ophthalmology-The Year in Review, 2022: Continued Evolution for Readers, Authors, and Editors by Bressler, Neil M

Get more information

Ophthalmology and COVID-19 by Bressler, Neil M

“…In this Viewpoint, JAMA Ophthalmology's editor reviews the known eye manifestations of COVID-19, the potential for ocular transmission of illness, and the…”
Get full text

Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks by Burlina, Philippe M, Joshi, Neil, Pekala, Michael, Pacheco, Katia D, Freund, David E, Bressler, Neil M

“…Age-related macular degeneration (AMD) affects millions of people throughout the world. The intermediate stage may go undetected, as it typically is…”
Get more information

Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply by Bressler, Neil M

Get more information

Reducing the Progression of Myopia by Bressler, Neil M

Get full text

JAMA Ophthalmology-The Year in Review, 2019: Striving for Sex Parity in Leadership and Excellence in Publications by Bressler, Neil M

Get more information

JAMA Ophthalmology-The Year in Review, 2020: Bringing Focus to Randomized Clinical Trials by Bressler, Neil M

Get more information

Age-Related Macular Degeneration Is the Leading Cause of Blindness by Bressler, Neil M

“…OBJECTIVE To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender…”
Get full text

Deep learning in ophthalmology: The technical and clinical considerations by Ting, Daniel S.W., Peng, Lily, Varadarajan, Avinash V., Keane, Pearse A., Burlina, Philippe M., Chiang, Michael F., Schmetterer, Leopold, Pasquale, Louis R., Bressler, Neil M., Webster, Dale R., Abramoff, Michael, Wong, Tien Y.

“…The advent of computer graphic processing units, improvement in mathematical models and availability of big data has allowed artificial intelligence (AI) using…”
Get full text

Use of Deep Learning for Detailed Severity Characterization and Estimation of 5-Year Risk Among Patients With Age-Related Macular Degeneration by Burlina, Philippe M, Joshi, Neil, Pacheco, Katia D, Freund, David E, Kong, Jun, Bressler, Neil M

“…Although deep learning (DL) can identify the intermediate or advanced stages of age-related macular degeneration (AMD) as a binary yes or no, stratified…”
Get more information

Low-Shot Deep Learning of Diabetic Retinopathy With Potential Applications to Address Artificial Intelligence Bias in Retinal Diagnostics and Rare Ophthalmic Diseases by Burlina, Philippe, Paul, William, Mathew, Philip, Joshi, Neil, Pacheco, Katia D, Bressler, Neil M

“…Recent studies have demonstrated the successful application of artificial intelligence (AI) for automated retinal disease diagnostics but have not addressed a…”
Get more information

Antiangiogenic Approaches to Age-Related Macular Degeneration Today by Bressler, Neil M., MD

“…Intravitreal ranibizumab reduces the risk of visual acuity loss and increases the chance of visual acuity gain compared with no treatment or photodynamic…”
Get full text

Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial by Bressler, Neil M, Kim, Taehyung, Oh, Inkyung, Russo, Paola, Kim, Mercy Yeeun, Woo, Se Joon

“…SB11 and reference ranibizumab (RBZ) are monoclonal anti-vascular endothelial growth factor (VEGF)-A antibodies approved for the treatment of neovascular…”
Get more information

Comparing Humans and Deep Learning Performance for Grading AMD: A Study in Using Universal Deep Features and Transfer Learning for Automated AMD Analysis by Burlina, Philippe, Pacheco, Katia D, Joshi, Neil, Freund, David E, Bressler, Neil M

“…Abstract Background: When left untreated, age-related macular degeneration (AMD) is the leading cause of vision loss in people over fifty in the US. Currently…”
Get full text

Prevalence of and risk factors for diabetic macular edema in the United States by Varma, Rohit, Bressler, Neil M, Doan, Quan V, Gleeson, Michelle, Danese, Mark, Bower, Julie K, Selvin, Elizabeth, Dolan, Chantal, Fine, Jennifer, Colman, Shoshana, Turpcu, Adam

“…Diabetic macular edema (DME) is a leading cause of vision loss in persons with diabetes mellitus. Although there are national estimates for the prevalence of…”
Get more information

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results by Elman, Michael J., MD, Ayala, Allison, MS, Bressler, Neil M., MD, Browning, David, MD, Flaxel, Christina J., MD, Glassman, Adam R., MS, Jampol, Lee M., MD, Stone, Thomas W., MD

“…Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks)…”
Get full text